Bromfenac
- Generic Name
- Bromfenac
- Brand Names
- Bromday, Bromsite, Prolensa, Xibrom, Yellox
- Drug Type
- Small Molecule
- Chemical Formula
- C15H12BrNO3
- CAS Number
- 91714-94-2
- Unique Ingredient Identifier
- 864P0921DW
- Background
Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) for ophthalmic use. Ophthalmic NSAIDs are becoming a cornerstone for the management of ocular pain and inflammation. Their well-characterized anti-inflammatory activity, analgesic property, and established safety record have also made NSAIDs an important tool for optimizing surgical outcomes. Non-ophthalmic formulations of bromfenac were withdrawn in the US in 1998 due to cases of severe liver toxicity.
- Indication
For the treatment of postoperative inflammation in patients who have undergone cataract extraction.
- Associated Conditions
- Eye Pain, Ocular Inflammation
Study to Compare Differing Dosing Regimens of ISV-303 (Bromfenac in DuraSite) to Xibrom and Vehicle in Post Cataract Surgery Volunteers
- Conditions
- Ocular Inflammation
- Interventions
- First Posted Date
- 2010-08-30
- Last Posted Date
- 2021-11-19
- Lead Sponsor
- Sun Pharmaceutical Industries Limited
- Target Recruit Count
- 169
- Registration Number
- NCT01190878
A Comparison of Post Phacoemulsification Aqueous Flare in Patients Using Ketorolac 0.45% 2 Times Daily (BID) and Bromfenac 0.09% 2 Times Daily (BID)
- Conditions
- Post Operative Anterior Chamber Inflammation (Flare)
- Interventions
- First Posted Date
- 2009-12-02
- Last Posted Date
- 2011-08-26
- Lead Sponsor
- Bucci Laser Vision Institute
- Target Recruit Count
- 50
- Registration Number
- NCT01023724
- Locations
- 🇺🇸
Bucci Laser Vision Institute, Wilkes-Barre, Pennsylvania, United States
A Comparison of Prostaglandin E2 (PGE2) Inhibition of Acuvail(Ketorolac 0.45%), Xibrom (Bromfenac 0.09%)and Nevanac (Nepafenac)in Patients Undergoing Phacoemulsification
- Conditions
- Cataracts
- Interventions
- First Posted Date
- 2009-11-30
- Last Posted Date
- 2011-08-31
- Lead Sponsor
- Frank A. Bucci, Jr., M.D.
- Target Recruit Count
- 126
- Registration Number
- NCT01021761
A Comparison of Peak Aqueous Penetration of Acuvail (Ketorolac 0.45%), Xibrom (Bromfenac 0.09%), and Nevanac (Nepafenac 0.1%)in Patients Undergoing Phacoemulsification
- Conditions
- Cataracts
- Interventions
- First Posted Date
- 2009-10-27
- Last Posted Date
- 2011-10-03
- Lead Sponsor
- Frank A. Bucci, Jr., M.D.
- Target Recruit Count
- 126
- Registration Number
- NCT01001806
- Locations
- 🇺🇸
Bucci Laser Vision Institute, Wilkes-Barre, Pennsylvania, United States
Efficacy Study of Bromfenac Ophthalmic Solution in Patients Undergoing Cataract Surgery
- Conditions
- PainInflammation
- Interventions
- Drug: Placebo Comparator
- First Posted Date
- 2009-03-02
- Last Posted Date
- 2013-01-25
- Lead Sponsor
- Bausch & Lomb Incorporated
- Target Recruit Count
- 299
- Registration Number
- NCT00853970
- Locations
- 🇺🇸
ISTA Pharmaceuticals, Inc., Irvine, California, United States
Evaluation of Comfort With Xibrom (Bromfenac Ophthalmic Solution)0.09% and Nevanac (Nepafenac Ophthalmic Suspension) 0.1% Following Selective Laser Trabeculoplasty (SLT)
- First Posted Date
- 2009-01-26
- Last Posted Date
- 2009-06-10
- Lead Sponsor
- Bp Consulting, Inc
- Target Recruit Count
- 25
- Registration Number
- NCT00828477
- Locations
- 🇺🇸
Coburn-Kleinfeldt Eye Clinic, 3340 6 mile Rd Livonia, Michigan, United States
Determination of Optimum Duration of Treatment With Bromfenac (Xibrom) Eyedrops Following Cataract Surgery
- Conditions
- Cataracts
- Interventions
- First Posted Date
- 2008-09-25
- Last Posted Date
- 2012-03-15
- Lead Sponsor
- Bp Consulting, Inc
- Target Recruit Count
- 49
- Registration Number
- NCT00758199
- Locations
- 🇺🇸
Altos Eye Physicians, Los Altos, California, United States
Safety and Efficacy of an Ophthalmic Solution in Dry Eye Disease
- First Posted Date
- 2008-09-25
- Last Posted Date
- 2020-09-14
- Lead Sponsor
- Bausch & Lomb Incorporated
- Target Recruit Count
- 38
- Registration Number
- NCT00758784
- Locations
- 🇺🇸
ISTA Pharmaceuticals, Inc., Irvine, California, United States
Efficacy and Safety of Bromfenac Ophthalmic Solution in Cataract Surgery
- First Posted Date
- 2008-06-24
- Last Posted Date
- 2013-01-18
- Lead Sponsor
- Bausch & Lomb Incorporated
- Target Recruit Count
- 156
- Registration Number
- NCT00704418
- Locations
- 🇺🇸
ISTA Pharmaceuticals, Inc., Irvine, California, United States
Efficacy and Safety of Bromfenac Ophthalmic Solution in Cataract Surgery
- First Posted Date
- 2008-06-24
- Last Posted Date
- 2015-03-24
- Lead Sponsor
- Bausch & Lomb Incorporated
- Target Recruit Count
- 126
- Registration Number
- NCT00703781
- Locations
- 🇺🇸
ISTA Pharmaceuticals, Inc., Irvine, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.